What is Driving a Strong Bullish Sentiment Towards Viking Therapeutics (VKTX)

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 best biotech stocks with highest upside potential.

Back on March 26, Viking Therapeutics Inc. (NASDAQ:VKTX) reported the final recruitment of patients into the Phase 3 VANQUISH-2 study of its investigational subcutaneous drug VK2735, a dual agonist of the GLP-1 and GIP receptors. The drug is being studied for oral and subcutaneous administration in the treatment of various metabolic diseases.

Sergey Nivens/Shutterstock.com

Furthermore, Viking is performing the Phase 3 VANQUISH-1 trial of VK2735 administered subcutaneously to patients for the treatment of obesity or being overweight. The enrollment for the VANQUISH-1 trial was completed in November 2025. Additionally, Viking is performing a Phase 1 trial assessing multiple maintenance dosing strategies for VK2735. The primary goals of the trial involve assessing the safety, tolerability, and pharmacokinetics of VK2735 administered under various dosing schemes.

Secondary goals measure the body weight changes from the baseline and after the switch to maintenance dosing. The results of this trial are expected to be announced in the third quarter of 2026.

Viking Therapeutics Inc. (NASDAQ:VKTX) specializes in metabolic and endocrine disorder therapies. As a clinical-stage biopharmaceutical company, they direct their research efforts towards small-molecule drugs to cure obesity, fatty liver, and diabetes.

While we acknowledge the risk and potential of VKTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VKTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.